Scarica l'app Stockscreener
3.75
3.87%
0.13
Voyager Therapeutics Inc Borsa (VYGR) Ultime notizie
VYGRVoyager Therapeutics Inc Latest SEC Filings - Finviz
Enterprise value to revenue forward of Voyager Therapeutics, Inc. – NASDAQ:VYGR - TradingView
Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside - Insider Monkey
Price to sales forward of Voyager Therapeutics, Inc. – NASDAQ:VYGR - TradingView
Price to sales forward of Voyager Therapeutics, Inc. – FWB:VT6 - TradingView
Enterprise value to revenue forward of Voyager Therapeutics, Inc. – FWB:VT6 - TradingView
Price to earnings forward of Voyager Therapeutics, Inc. – NASDAQ:VYGR - TradingView
Enterprise value to EBITDA forward of Voyager Therapeutics, Inc. – NASDAQ:VYGR - TradingView
Price to book forward of Voyager Therapeutics, Inc. – FWB:VT6 - TradingView
Voyager to present Alzheimer’s gene therapy data at AAIC - Investing.com UK
Voyager to present Alzheimer’s gene therapy data at AAIC By Investing.com - Investing.com Australia
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s - GlobeNewswire
VYGR Forecast — Price Target — Prediction for 2027 - TradingView
Voyager Therapeutics, Inc. Actuals & Estimates (NASDAQ:VYGR) - TradingView
H.C. Wainwright Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR) - The Globe and Mail
Voyager Therapeutics, Inc. Actuals & Estimates (MUN:VT6) - TradingView
VT6 Forecast — Price Target — Prediction for 2027 - TradingView
H.C. Wainwright Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Voyager Therapeutics Inc (VYGR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Voyager Therapeutics Inc (VYGR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Voyager Therapeutics Inc (VYGR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Voyager Therapeutics Inc (VYGR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TD Cowen Maintains Voyager Therapeutics(VYGR.US) With Buy Rating - Moomoo
Voyager Therapeutics, Inc. Stock 12‑Month Price Target Raised to $15.38, Implies 325% Upside - TradingView
Voyager Therapeutics Inc (VYGR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Voyager Therapeutics Inc (VYGR) Institutional Confidence - TradingKey
Voyager Therapeutics Inc (VYGR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Voyager Therapeutics Inc (VYGR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Voyager Therapeutics Inc (VYGR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference - markets.businessinsider.com
Voyager Therapeutics (VYGR) director awarded 30,000 stock options at $3.43 - Stock Titan
Voyager Therapeutics (VYGR) grants director 30,000 stock options at $3.43 - Stock Titan
Voyager Therapeutics director granted 30,000 options | VYGR Insider Trading - Stock Titan
Voyager director granted options for 30,000 shares | VYGR Insider Trading - Stock Titan
Voyager Therapeutics (VYGR) director receives 30,000 stock options grant - Stock Titan
Voyager Therapeutics (VYGR) director granted 30,000 stock options at $3.43 - Stock Titan
Voyager Therapeutics (VYGR) grants director Glenn Pierce 30,000 stock options - Stock Titan
Voyager Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Onyia Jude - Moomoo
Voyager Therapeutics Expands Authorized Shares After Stockholder Vote - TipRanks
Voyager Therapeutics (NASDAQ: VYGR) doubles authorized common stock after 2026 vote - Stock Titan
Here's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Situation - Yahoo Finance
Guggenheim Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Voyager’s tau-targeted gene therapy VY-1706 gains IND approval - BioWorld News
Voyager gets FDA clearance for Alzheimer’s gene therapy trial By Investing.com - Investing.com India
Voyager Therapeutics (VYGR) Gains FDA Approval for Alzheimer's G - GuruFocus
Voyager Therapeutics Receives FDA Clearance to Begin Clinical Trial of VY1706 Gene Therapy for Alzheimer’s Disease - Minichart
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease - markets.businessinsider.com
Voyager Therapeutics IND Cleared for Alzheimer’s Gene Therapy - TipRanks
Voyager Therapeutics receives FDA clearance to begin Alzheimer’s gene therapy trial - Investing.com India
FDA clears Voyager Therapeutics (VYGR) IND for Alzheimer’s gene therapy VY1706 - Stock Titan
Voyager Receives FDA IND Clearance for VY1706, First Gene - GlobeNewswire
Voyager Therapeutics Stock Is Waking Up Before a Make-or-Break Tau Window - Bez Kabli
H.C. Wainwright reiterates Voyager Therapeutics stock rating on pipeline progress - Investing.com Australia
H.C. Wainwright reiterates Voyager Therapeutics stock rating on pipeline progress By Investing.com - Investing.com South Africa
1.16%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):